PPIDT00344
Drug Information
| Name | Inebilizumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB12530 |
| Type | biotech |
| Indication | Inebilizumab is indicated for the treatment of aquaporin-4 (AQP4) immunoglobulin-positive (AQP4-IgG) neuromyelitis optica spectrum disorder (NMOSD) in adult patients.[L14315] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
10 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
100 mg
|
| Solution | Intravenous |
10 mg / mL
|
| Solution, concentrate | Intravenous |
1000000 mg
|